Gliomas are the most common and devastating central nervous system neoplasms. A gender bias exists in their development: females are at lower risk than males, implicating estrogen-mediated protective effects. Estrogen functions are mediated by two ER subtypes: ERα, that functions as tumor promoter and ERβ that function as tumor suppressor. We examined the potential use of 
Introduction
Gliomas are the most common type of primary brain tumors that account for more than 70% of all primary brain tumors. Despite tremendous improvements in the standard therapies for patients with gliomas, patients with malignant gliomas have a survival time of approximately 12 months (1, 2) . To date, little is known about the etiology of gliomas except the high risk factor of exposure to high doses of ionizing radiation and the presence of rare genetic conditions like neurofibromatosis and tuberous sclerosis (3) (4) (5) .
Recent studies suggest a possible protective role of female sex hormones in glioma progression. The incidence of developing gliomas is greater in males than in females, and females of reproductive age have a survival advantage over males and menopausal females (6) (7) (8) (9) (10) . Estrogens are steroid hormones that play a crucial role during brain development and differentiation (11, 12) , and locally synthesized estrogens from androgens by cytochrome P450 aromatase (CYP19) play a critical role in neuroprotective functions (13) . Furthermore, lower glioma incidence with usage of exogenous hormones was evident in females (9, 14) .
Collectively, these findings suggest that estrogens play a critical role in differentiation and survival of neural cells; yet, little is known about therapeutic significance of estrogen signaling in glioma initiation and progression.
The biological effects of estrogens are preferentially mediated through their cognate receptors: estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) (15, 16) . Eventhough ERα and ERβ are structurally similar, their ligand-binding domains differ enough to be selective for different ligands (17) . Recent studies have shown that ERβ has quite a different function than ERα (18) and is generally considered a tumor suppressor. ERβ expression is down regulated or lost in several tumors including those of the breast, ovary, prostate, and colon (19) (20) (21) (22) .
Additionally, it has been reported that overexpression of ERβ reduced cell proliferation and knockdown of ERβ enhanced cell proliferation in colon and breast cancer cells (23) (24) (25) \ While the studies suggest that ERβ has tumor suppressive potential in some tumors, the role and therapeutic significance of ERβ signaling in gliomas remains elusive.
Recently, a number of selective ERβ agonists have been developed and are being investigated for therapeutic use (18) . Along these lines, a novel, highly selective ERβ-agonist named liquiritigenin was recently isolated from the Glycyrrhiza uralensis (26) . Liquiritigenin is an active compound found in MF101 (Menerba), a plant extract designed to treat vasomotor symptoms (hot flashes) associated with menopause. In a Phase II clinical trial of Menerba (27) , the drug was found to be safe, well tolerated and taken with high compliance. It is being further evaluated for its therapeutic use in a Phase III clinical trial (28) .
In the current study, we investigated the status and significance of ERβ signaling in gliomas through the use of both in vitro and in vivo xenograft models of gliomas, and tested its therapeutic significance using recently developed selective ERβ modulators. Our findings revealed that ERβ agonists promote both expression and tumor suppressive functions of ERβ.
Liquiritigenin, a plant-derived ERβ agonist significantly reduced in vivo tumor growth in a xenograft model. Our results suggest that ERβ signaling plays a tumor suppressive function in gliomas, and thus ERβ agonists represent a novel class of drugs for curbing glioma progression.
Materials and Methods

Cell lines and reagents
Human glioma cell lines T98G, U87, LN229, U138, M059J, M059K, MCF7, MDA-MB-231 were obtained from the American Type Culture Collection (ATCC) and were passaged in our laboratory for less than six months. Glioma cell lines were maintained in DMEM medium, and MCF7 and MDA-MB-231 cells were maintained in RPMI-1640 medium supplemented with 10% FBS (Hyclone Laboratories Ltd, Logan, UT). DPN and PPT was purchased from Tocris Bioscience (Ellisville, MO) and MF101 was obtained from Bionovo (Emeryville, CA).
Liquiritigenin was purchased from Biopurify Phytochemicals (Chengdu, China). The ERβ antibody and ERβ specific siRNA were obtained from Thermo Scientific (Waltham, MA). The ERα antibody was from Millipore (Billerica, MA). PCNA was from Cell Signaling Technology (Boston, MA). ERβ specific shRNA lentivirus, β-actin and all secondary antibodies were purchased Sigma Chemical Co (St. Louis, MO).
Cell lysis and Western blotting
Whole cell lysates were prepared from glioma cells in modified RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, 50 mM NaF, 5 mM EDTA, 0.5% [wt/vol] sodium deoxycholate and 1% Triton X-100) containing phosphatase and protease inhibitors. Lysates were run on 10% SDS-PAGE. Total proteins (30 μg) were mixed with SDS sample buffer and separated on SDSpolyacrylamide gels. Resolved proteins were transferred onto nitrocellulose membranes, and the membranes were blocked with 5% non-fat dry milk solution for 1 h at room temperature and incubated overnight in the primary antibodies at 4 0 C. Membranes were then incubated with the respective secondary antibodies for 1 h at room temperature and immunoreactivity was detected by using an ECL kit (GE Health Care, CA). Nuclear fractionation was performed using compartmental protein extraction kit (Millipore, Billerica, MA). U87 and LN229 cells were seeded in 6-well plates and maintained in phenol red-free DMEM medium with 5% deactivated charcoal stripped serum. To evaluate the transcriptional activity of endogenous ERβ, cells were transfected with 1 μg of the estrogen responsive element (ERE) construct (pGL2-TATA-3XEREs-Luc) using fugene for 6 h, and 24 h after transfection the cells were treated with vehicle (0.1% DMSO), DPN, MF101 and liquiritigenin for an additional 24 h. The β-galactosidase reporter plasmid (pCMVbetaGal) (20 ng) was co-transfected and used for data normalization. Luciferase activity was measured by using the luciferase assay system (Promega, Madison, WI) and luminometer. The luciferase activity was expressed as percent of relative light units versus untreated transfected cells.
Reporter gene assays
Cell proliferation and clonogenic assays
Cell proliferation rates were measured by using Cell Titer-Glo Luminescent Cell Luminometer. For some assays, ERβ mediated growth inhibition was determined using traditional MTT assays. Glioma cells stably expressing ERβ-shRNA were generated using human specific Lentiviral ERβ-shRNA particles. Stable clones were selected with puromycin selection (1 μg/mL) and pooled clones were used for all the studies. Lentiviral particles expressing nontargeted short hairpin RNA (shRNA) were used to generate control cells. Colonies that contain ≥ 50 cells were counted.
Flow Cytometry
U87 and LN229 cells were seeded in 100-mm culture plates, synchronized by serum starvation for 48h and treated with liquiritigenin or 0.1% DMSO for 48 h. Cells were then trypsinized and harvested in 1X PBS, followed by fixation in ice cold 70% ethanol. Staining was done with a mixture of 50 μg/mL propidium iodide (PI) and 50 μg/mL RNase A. Then, PIstained cells were subjected to flow cytometry by using a FACS analysis using UTHSCSA core facility. the β-actin transcript levels and the difference in fold expression was calculated using deltadelta-CT method.
Quantitative RT-PCR analysis
Immunofluorescence studies
Confocal microscopy was performed as previously described (29) . U87 and LN229 cells were seeded on sterile glass cover slips in 24-well plates and treated with vehicle (0.1% DMSO) or liquiritigenin for 24 h. The cells were fixed with 3.7% paraformaldehyde for 15 min followed by permeabilization with 0.2% Triton X-100 in PBS. After blocking with 5% normal goat serum (Sigma) for 1 h, the cells were incubated with the ERβ primary antibody for 1 h. The ERβ status was analyzed by phalloidin staining for 1 h at room temperature. The DNA dye 4',6-diamidino-2-phenylindole (Invitrogen) was used to co-stain the DNA (blue). Fluorescence was captured using a Leica confocal microscope.
Tissue microarrays
The tissue microarrays (TMAs) were obtained from US BioMax (Rockville, MD). Each TMA comprised 0.6-mm cores taken from paraffin-embedded specimens that represent a total of 192 glioma tissues and 8 each of adjacent normal tissue and normal tissues.
Immunohistochemistry
Immunohistochemical analysis was performed as described (29) . Tumor sections were 
Nude mice studies
All animal experiments were performed after obtaining UTHSCSA-IACUC approval and the animals were housed in accordance with UTHSCSA institution's protocol for animal experiments. For xenograft tumor assays, 1 x 10 6 U87 cells were mixed with an equal volume of matrigel and implanted subcutaneously into the flanks of 6-week-old female nude mice as described (33) . Once tumors reached measurable size, mice were divided into control and treatment groups. The control group received vehicle (0.3% hydroxyl propyl cellulose), and the treatment group received liquiritigenin (20 mg/kg) subcutaneously once a day for 30 days.
Tumor volumes were measured with a caliper at 5-day intervals. After the 30 th day, the mice were euthanized, and the tumors were isolated and processed for histological studies. Tumor volume was calculated by using a modified ellipsoidal formula: tumor volume = ½ (L x W2), where L is the longitudinal diameter and W is the transverse diameter (33) . Body weight was measured at weekly intervals to rule out the drug toxicity.
Statistical analysis
SPSS software was used for all statistical analyses. A Student's t-test was used to assess statistical differences between control and liquiritigenin-treated groups. The level of significance was set at P<0.05. Statistical differences among groups were analyzed with ANOVA . 
Results
Gliomas express ERβ and nuclear expression of ERβ negatively correlates with histological malignancy
Several investigations demonstrated weak or low expression for ERα in gliomas.
However, very little is known on the status of ERβ in glial tumors. We used a glioma TMA to investigate whether ERβ expression correlates with the clinical grade of gliomas or adjacent normal brain tissues. We measured the expression levels of ERβ by IHC, and intensity was scored as previously described (29) (30) (31) . The representative staining for each grade is shown in (Fig. 1E) . These results suggest that ERβ expression was low during the progression of gliomas and that high grade gliomas express ERβ predominantly in the cytoplasm.
Glioma cells have a functional ERβ signaling pathway
To understand the significance of the ER pathway in glioma progression, we examined the status of ERα and ERβ expression in various glioma cell lines. MCF7 and MDA-MB-231 breast cancer cells were used as positive controls for ERα and ERβ, respectively ( Fig. 2A) Supplementary   Fig. S1 ), Results of these experiments demonstrate the specificity of ERβ antibody used in this study. To examine the functionality of ERβ signaling in glioma cells, we used ligands that uniquely activate ERβ including DPN, MF101 and liquiritigenin. MF101 is derived from 22 herbs and is currently in clinical trials for hot flashes (28) . Structure of DPN and liquiritigenin is depicted in Supplementary Fig. 2 . Using reporter gene assays, we found that ERβ agonist treatment significantly enhanced the ERE-luciferase activity in U87 and LN229 glioma cell lines (Fig. 2B) . To further confirm the functional activation of the ERβ transcriptional pathway, we examined the expression of ERβ target genes under conditions of ERβ agonist stimulation.
Ligand stimulation enhanced the expression of the ERβ target genes MSMB, MDA-7 and NKG2E
( Fig. 2C and D) . Collectively, these results suggest that glioma cells express ERβ and that ERβ is functionally active.
ERβ agonists reduce the proliferation of glioma cells
Emerging evidence suggest that ERβ functions as tumor suppressor. We therefore examined whether activation of ERβ pathway by agonists contribute to reduction of proliferation in four different glioma model cells. Treatment of glioma cells with MF101, DPN and liquiritigenin resulted in a significant dose-dependent reduction in cell proliferation (Fig. 3A) .
Knockdown of ERβ expression using either siRNA or shRNA, abolished the ability of ERβ ligands to reduce the proliferation of glioma cells (Supplementary Fig. S3 ). Similarly, treatment of ERα specific agonist propyl-pyrazole triol (PPT) did not showed any inhibitory effect on the proliferation of glioma cells (Supplementary Fig. S4 ). In cell survival assays, ERβ agonists significantly reduced the colony formation ability of glioma cells (Fig. 3B) 
of glioma cells revealed that ERβ agonist treatment causes cell cycle arrest most significantly in G2/M phase in both model cells (Fig. 3C) . Further, ERβ agonist also showed significant effect on S phase accumulation in addition to G2/M arrest in LN229 cells. Collectively, these results suggest that ERβ agonists have potential to block cell cycle progression of glioma cells and preferentially arrest them at the G2/M phase of cell cycle.
Liquiritigenin induces the expression and nuclear translocation of ERβ
Earlier studies suggested autoregulation of ERβ by its ligand estrogen. We therefore examined whether ERβ agonist treatment increases expression of ERβ by using RT-qPCR assay.
The results revealed that liquiritigenin enhanced the expression of ERβ (Fig. 4A ). In agreement with the RT-PCR results, Western analysis of cell lystaes revealed that ERβ protein expression was also significantly increased in glioma cells following liquiritigenin treatment (Fig. 4B ).
Since most of the ERβ staining was found in the cytoplasm in high-grade tumors, we determined whether liquiritigenin treatment promoted localization of ERβ to the nuclear compartment.
Confocal microscopy revealed that most of the ERβ expression was confined to the cytoplasm in U87 and LN229 glioma cells; however, liquiritigenin treatment significantly induced the nuclear translocation of ERβ in these cells (Fig. 4C and D, upper panels) . Biochemical fractionation and Western analysis also confirmed increased nuclear translocation of ERβ upon liquiritigenin treatment ( Fig. 4C and D, bottom panels) . These results suggest that activation of ERβ pathway via agonists has potential to increase ERβ protein expression and nuclear translocation. To examine whether the ERβ agonist liquiritigenin inhibits growth of glioma cells in vivo, we used a nude mouse-based subcutaneous xenograft assay. Two weeks after subcutaneous implantation of U87 glioma cells and when xenograft tumors reached measurable size, liquiritigenin or vehicle was given subcutaneously at a dose of 20 mg/kg/mice/day. Tumor volume was measured for every five days. After 30 days of treatment, the mice were euthanized.
As shown in Fig 5A, the rate of tumor growth was significantly reduced in liquiritigenin-treated mice. No toxicities were observed as determined by behavioral changes, such as eating habits and mobility in animals treated with liquiritigenin, and mouse weights were not significantly different between control and liquiritigenin-treated groups (Fig. 5B) . Furthermore, TUNEL analysis showed that the number of apoptotic cells was significantly higher in liquiritigenintreated mice than in the control mice (Fig. 5C ). The proliferation rate of tumor cells was significantly lower in the liquiritigenin-treated mice, which was evident from the reduced PCNA expression (Fig. 5D ). ERβ expression and nuclear localization was significantly greater upon liquiritigenin treatment (Fig. 5D ). Overall these results suggest that liquiritigenin can restore ERβ expression in gliomas and has potential to suppress glioma cell proliferation in vivo.
Discussion
Gliomas are the most common and deadliest form of primary central nervous system neoplasms. Steroid hormones play crucial roles during brain development and differentiation (11, 12) . Several lines of evidence suggest that the incidence of brain tumors is significantly higher in males than in reproductive-aged females suggesting the possible protective role of female sex hormones in the development of brain tumors (6) (7) (8) (9) (10) . However, a molecular mechanism through which estrogen may mediate protection against the gliomas remains elusive. In this study, we examined the significance and therapeutic potential of ERβ signaling in glioma progression using ERβ-specific ligands. We found that (1) with the higher tumor grade. We also observed that ERβ was localized in the cytoplasm in most of the high-grade tumors and glioma cell lines. ERβ overexpression is shown to promote the differentiation of tumor cells and ERβ agonist 3β-adiol was necessary for maintaining epithelial phenotype (35) . Our results collaborate with recently published TMA studies that suggest reduced ERβ signaling may be a prognostic marker for gliomas (32, 33) . These findings suggest agonists that increase or stabilize the ERβ expression may have clinical utility in reducing glioma tumor growth.
Currently, various ERβ-selective drugs including DPN, ERB-041, MF101, liquiritigenin are being investigated as a replacement for estrogens to treat menopausal symptoms (17, 18) . 
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